Urgent Need for Genomics Information
We are a global coordinated team of clinical experts and researchers performing genomics and utilizing deep learning tools to correlate with clinical data in a prospective longitudinal study.
- There are no large scale longitudinal genomic studies in T-cell lymphomas to understand refractoriness and relapse. This initiative is desperately needed.
- Genomics via Next generation sequencing (NGS) enables the characterization of the somatic and germline defects in individual tumor samples which is needed for identifying therapeutic options.
- Genomics can reveal personalized targetable aberrations, mutational burden, complex molecular signatures, tumor-specific antigens which will inform utilization of diverse therapies from targeted drugs, epigenetic modifiers, small molecule inhibitors and cellular therapies.
- The occurrence of common alterations across diverse T-cell lymphoma types will prompt new paradigms in the application of genomic profiling and the design of clinical trials.